LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

19.62 1.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.24

Максимум

19.77

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+105.06% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-77M 1.8B
Предишно отваряне	18.59
Предишно затваряне	19.62

Настроения в новините

By Acuity

50%

156 / 344 Класиране в Healthcare

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.05.2026 г., 22:47 ч. UTC

Печалби

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28.05.2026 г., 20:45 ч. UTC

Печалби

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28.05.2026 г., 23:31 ч. UTC

Пазарно говорене

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.05.2026 г., 22:41 ч. UTC

Пазарно говорене

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28.05.2026 г., 22:37 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

M&A-Related Insurance Payments In North America Rise -- Market Talk

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28.05.2026 г., 22:04 ч. UTC

Придобивния, сливания и поглъщания

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28.05.2026 г., 21:12 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28.05.2026 г., 21:00 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28.05.2026 г., 20:57 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:55 ч. UTC

Печалби

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

28.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

28.05.2026 г., 20:48 ч. UTC

Горещи акции

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28.05.2026 г., 20:34 ч. UTC

Печалби

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28.05.2026 г., 20:31 ч. UTC

Печалби

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28.05.2026 г., 20:28 ч. UTC

Печалби

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28.05.2026 г., 20:26 ч. UTC

Печалби

Dell Stock Soars on Blowout Earnings -- Barrons.com

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Membership Fees $1.37B

28.05.2026 г., 20:20 ч. UTC

Печалби

Costco 3Q Net Sales $69.15B

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28.05.2026 г., 20:19 ч. UTC

Печалби

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28.05.2026 г., 20:17 ч. UTC

Печалби

Costco 3Q Same-Store Sales Up 9.8% >COST

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

105.06% нагоре

12-месечна прогноза

Среден 40.5 USD 105.06%

Висок 57 USD

Нисък 29 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

156 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.